Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease

The anti-CD20 antibody ocrelizumab, approved for treatment of multiple sclerosis, leads to rapid elimination of B cells from the blood. The extent of B cell depletion and kinetics of their recovery in different immune compartments is largely unknown. Here, we studied how anti-CD20 treatment influenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Häusler, Darius, Häusser-Kinzel, Silke, Feldmann, Linda, Torke, Sebastian, Lepennetier, Gildas, Bernard, Claude C. A., Zamvil, Scott S., Brück, Wolfgang, Lehmann-Horn, Klaus, Weber, Martin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2018
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166805/
https://www.ncbi.nlm.nih.gov/pubmed/30194232
http://dx.doi.org/10.1073/pnas.1810470115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166805/
https://www.ncbi.nlm.nih.gov/pubmed/30194232
http://dx.doi.org/10.1073/pnas.1810470115

Ejemplares similares